PE
MRK icon

PCM Encore’s Merck MRK Stock Holding History

PCM Encore’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Sell
17,958
-35
-0.2% -$4.1K 0.41% 47
2026
Q1 		$2.16M Buy
17,993
+897
+5% +$104K 0.45% 41
2025
Q4 		$1.8M Buy
+17,096
New +$1.6M 0.38% 48

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCM Encore's MRK Position: Q2 2026 in Review

PCM Encore reduced its Merck (MRK) stake by 0.19% in Q2 2026, selling an estimated $4.1K and leaving 17,958 shares worth $2.31M. The position accounts for 0.41% of the portfolio, ranked #47.

PCM Encore first reported a position in MRK in Q4 2025 and has held it in 3 quarters since. 3,829 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • PCM Encore held 17,958 shares of Merck worth $2.31M as of Q2 2026.
  • PCM Encore sold 35 Merck shares in Q2 2026, an estimated $4.1K.
  • Merck made up 0.41% of PCM Encore's portfolio in Q2 2026, its #47 holding.
  • PCM Encore first reported a position in Merck in Q4 2025 and has held it in 3 quarters since.
  • 3,829 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.